SCHEMBL217584

SCHEMBL217584

OCc1ccnc(-c2ccc3nc(-c4cnc5ccccc5c4)cn3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.47
CYP2C9 P11712 1/20 0.47
KCNH2 Q12809 1/20 0.47
MAPKAPK2 P49137 3/20 0.41
ALDH1A3 P47895 7/20 0.40
ALDH1A1 P00352 2/20 0.40
ALDH1A2 O94788 1/20 0.40
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
SLC2A1 P11166 1/20 0.38
CYP2A6 P11509 1/20 0.36
MAP4K4 O95819 2/20 0.36
CSNK1G2 P78368 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
MKNK2 Q9HBH9 2/20 0.36
PLK4 O00444 1/20 0.36
DAPK3 O43293 1/20 0.36
DYRK3 O43781 1/20 0.36
PRKD3 O94806 1/20 0.36
CHEK2 O96017 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3432955 0.86 NR4A2 (0.65) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1
SCHEMBL220148 0.85 NR4A2 (0.60) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1
Hydrochloric Acid SCHEMBL6522828 0.85 NR4A2 (0.64) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1
SCHEMBL216667 0.81 CDK8 (0.50) NR4A2CYP2C9KCNH2PDGFRBPDGFRA
SCHEMBL3435794 0.81 NR4A2 (0.52) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1
SCHEMBL220484 0.80 NR4A2 (0.69) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1
SCHEMBL6519711 0.78 NR4A2 (0.55) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1
SCHEMBL217708 0.78 ALDH1A3 (0.42) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1
SCHEMBL217710 0.78 NR4A2 (0.40) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1
SCHEMBL219106 0.78 NR4A2 (0.48) NR4A2CYP2C9KCNH2ALDH1A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262804-B1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-12-03 EP claimed
US-8598166-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2013-12-03 US claimed
US-8088765-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US claimed
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
EP-2262804-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-aventis (FR) 2010-12-22 EP claimed
WO-2009144392-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO claimed
US-8598166-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2013-12-03 US disclosed
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-03-01 US disclosed
US-8088765-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US disclosed
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 NR4A2 829/4885CYP2C9 97/4885KCNH2 2469/4885
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 NR4A2 829/4885CYP2C9 97/4885KCNH2 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.